This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fully Canine Antibody Development
Therapeutic antibodies derived entirely from canine sequences, without any mouse or human sequences, are better suited to adapt to the physiology and immune system of canines compared to heterologous antibodies. BioVenic provides fully canine antibody development services. By establishing major platforms, including hybridoma technology, transgenic animal model, phage display, and single B-cell technology, we assist in developing fully canine antibodies, which reduces the risks associated with heterologous antibodies and improves the efficacy of canine disease treatment at the same time.
Fully Canine Antibody Development Based on Hybridoma Technology
Hybridoma technology remains a cornerstone in canine therapeutic antibody development. Hybridoma involves the fusion of canine B-cells with myeloma cells, creating hybrid cells that can produce monoclonal antibodies. These antibodies are fully canine, ensuring high compatibility and reduced risk of immunogenicity in canine patients. Our services include custom-design to elicit robust immune responses in dogs, fusion of canine B-cells with myeloma cells to produce stable monoclonal antibody-secreting cell lines, as well as identifying and validating high-performance canine monoclonal antibodies for preclinical therapeutic development.
Fully Canine Antibody Development Based on Phage Display
The phage display antibody library technology is a novel genetic engineering antibody technique formed by combining antibody gene library technology with phage display technology. BioVenic has established a phage display platform, utilizing this technology to assist in fully canine antibody development. We provide phage antibody library construction services and utilize biopanning to rapidly identify phages with high affinity for specific targets from a large number of phages. BioVenic also provides diverse antibody expression systems to express and purify these antibodies in suitable host cells to obtain high-quality fully canine antibodies.
Fully Canine Antibody Development Based on Single B-Cell Technology
BioVenic has established the veterinary therapeutic antibody single B cell platform. Our team utilizes advanced single B cell antibody development technology, specifically catering to the research and treatment needs for canine diseases, offering comprehensive development services for fully canine antibodies. Our professionals collect B cell samples from immunized dogs, precisely identifying and isolating B cells that produce a specific antigen response. We also accurately identify and clone the heavy and light chain gene sequences of the target antibody. These sequences are then expressed and purified in specialized host cell lines. We offer antibody affinity assays to ensure that antibody samples produced have high affinity in the canine body.
Fully Canine Antibody Development Based on Transgenic Animal Model
Fig.1 How to get the fully canine antibody? (BioVenic Original)
Establishing the canine antibody gene mouse model involves introducing or replacing the canine antibody genome with the corresponding murine antibody genome. BioVenic has established the transgenic mouse platform for fully canine antibody development. Our professionals utilize bacterial artificial chromosome (BAC) technology to design transgenic mice carrying key gene fragments of the canine immune system. Combined with our veterinary therapeutic antibody hybridoma technology, these transgenic mice are immunized with antigens to obtain hybridoma cells and synthesize fully canine antibodies. Depending on specific needs, we provide antigen expression services, including but not limited to various types of antigens such as proteins, peptides, DNA, mRNA, and VLPs, complemented by antigen detection services, to ensure optimal immunization results in subsequent stages.
Why Choose Us?
Accurately and precisely transplant the canine antibody gene to the exact location of the murine genome, providing high-quality transgenic mice.
Rich experience in phage library construction, constructing large-capacity phage display libraries of canine antibodies.
Single B-cell technology is utilized to accomplish rapid delivery of fully canine antibodies while preserving the natural pairing of VH and VL.
Full-process service makes it possible to advance the project faster and more conveniently.
Residual heterologous components after caninization treatment may still activate the canine immune system. Utilizing cutting-edge technologies, BioVenic provides comprehensive services for fully canine antibody development. Transgenic mice generate antibodies in vivo, ensuring high target-binding affinity. Phage display eliminates the need for animal immunization. Single B cell technology offers higher efficiency. If you require fully canine antibody development, please do not hesitate to contact us now!